Why the study?
Adiponectin levels paradoxically increase with heart failure severity and predict poor prognosis, driving interest in adiponectin as a marker of disease progression and prognosis.
Key points are not available for this paper at this time.
Design
Review
Paradoxical adiponectin rise in HF may mark progression; leaves open its biomarker or therapeutic value.
The adipose tissue, apart from storing energy, plays a role of an endocrine organ. One of the most important adipokines secreted by adipose tissue is adiponectin, which is also produced by cardiomyocytes and connective tissue cells within the heart. Adiponectin is known for its beneficial effect on the metabolism and cardiovascular system and its low level is a factor of development of many cardiovascular diseases. Paradoxically, in the course of heart failure, adiponectin level gradually increases with the severity of the disease and higher adiponectin level is a factor of poor prognosis. As a result, there is a growing interest in adiponectin as a marker of heart failure progression and a predictor of prognosis in the course of this disease.
No takes yet. Share an insight, caveat, or question.
Mado et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: